145 related articles for article (PubMed ID: 12140146)
1. Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer.
Billingham LJ; Bathers S; Burton A; Bryan S; Cullen MH
Lung Cancer; 2002 Aug; 37(2):219-25. PubMed ID: 12140146
[TBL] [Abstract][Full Text] [Related]
2. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P
Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of hospital at home versus hospital care: cost minimisation analysis of data from randomised controlled trial.
Jones J; Wilson A; Parker H; Wynn A; Jagger C; Spiers N; Parker G
BMJ; 1999 Dec; 319(7224):1547-50. PubMed ID: 10591720
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
Earle CC; Evans WK
Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
[TBL] [Abstract][Full Text] [Related]
5. Cost analysis of hospital treatment--two chemotherapic regimens for non-surgical non-small cell lung cancer. GFPC (Groupe Français Pneumo Cancérologie).
Vergnenègre A; Perol M; Pham E
Lung Cancer; 1996 Feb; 14(1):31-44. PubMed ID: 8696719
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
Palmer AJ; Brandt A
Monaldi Arch Chest Dis; 1996 Aug; 51(4):279-88. PubMed ID: 8909011
[TBL] [Abstract][Full Text] [Related]
7. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
Holmes J; Dunlop D; Hemmett L; Sharplin P; Bose U
Pharmacoeconomics; 2004; 22(9):581-9. PubMed ID: 15209527
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
10. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.
Berthelot JM; Will BP; Evans WK; Coyle D; Earle CC; Bordeleau L
J Natl Cancer Inst; 2000 Aug; 92(16):1321-9. PubMed ID: 10944554
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
Evans WK
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
Thongprasert S; Permsuwan U; Ruengorn C; Charoentum C; Chewaskulyong B
Asia Pac J Clin Oncol; 2011 Dec; 7(4):369-75. PubMed ID: 22151987
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of nurse led intermediate care versus standard care for post-acute medical patients: cost minimisation analysis of data from a randomised controlled trial.
Walsh B; Steiner A; Pickering RM; Ward-Basu J
BMJ; 2005 Mar; 330(7493):699. PubMed ID: 15757959
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
16. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
17. Home-based cardiac rehabilitation versus hospital-based rehabilitation: a cost effectiveness analysis.
Taylor RS; Watt A; Dalal HM; Evans PH; Campbell JL; Read KL; Mourant AJ; Wingham J; Thompson DR; Pereira Gray DJ
Int J Cardiol; 2007 Jul; 119(2):196-201. PubMed ID: 17084927
[TBL] [Abstract][Full Text] [Related]
18. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.
Cullen MH; Billingham LJ; Woodroffe CM; Chetiyawardana AD; Gower NH; Joshi R; Ferry DR; Rudd RM; Spiro SG; Cook JE; Trask C; Bessell E; Connolly CK; Tobias J; Souhami RL
J Clin Oncol; 1999 Oct; 17(10):3188-94. PubMed ID: 10506617
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
Leighl NB; Shepherd FA; Kwong R; Burkes RL; Feld R; Goodwin PJ
J Clin Oncol; 2002 Mar; 20(5):1344-52. PubMed ID: 11870178
[TBL] [Abstract][Full Text] [Related]
20. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer.
Billingham LJ; Cullen MH
Ann Oncol; 2001 Dec; 12(12):1671-5. PubMed ID: 11843243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
